Compare Dolby Laboratories, Inc. (DLB) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs IDEXX Laboratories, Inc. — how do they compare? Dolby Laboratories, Inc. trades at $61.2 (market cap $5.75B), while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 8× Dolby Laboratories, Inc.'s market cap, and Dolby Laboratories, Inc. pays a 2.35% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| DLB | IDXX | |
|---|---|---|
Market Cap | $5.75B | $46.22B |
Sector | Industrials | Health |
52-Week High | $75.62 | $766.68 |
52-Week Low | $48.51 | $526.44 |
Enterprise Value | $5.12B | $47.12B |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dolby Laboratories (DLB) trades at $60.74, down 2.19% on the day, with a bullish technical outlook supported by moving averages. The company maintains strong profitability with an 87.61% gross margin and has beaten EPS estimates for four consecutive quarters. Recent news highlights innovation in automotive and broadcast licensing, though revenue growth remains choppy.
The stock presents a compelling opportunity with a consensus price target of $87.50, implying significant upside, but faces near-term execution risks and licensing volatility. Long-term growth drivers in premium audio/visual formats are balanced by macroeconomic sensitivity and competitive pressures.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
